Diagnosis of Myocardial Ischemia With MCG Using SPECT as a Reference Standard

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Feb 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new method called Magnetocardiography (MCG) to see how well it can detect a heart condition known as myocardial ischemia, which is when the heart doesn't get enough blood. Researchers are comparing MCG to a well-established imaging technique called Single Photon Emission Computed Tomography (SPECT), which is considered the gold standard for diagnosing this condition. The goal is to find out if MCG can be a reliable way to help doctors identify patients who may be experiencing chest pain due to heart issues.

To be eligible for this trial, participants need to be at least 18 years old and experiencing symptoms related to myocardial ischemia, such as chest pain. They should have results from a coronary angiogram (CAG) or a computed tomography angiography (CTA) showing mild blockages in their heart arteries. If you decide to participate, you will undergo MCG testing along with SPECT imaging to see how well these methods work together. It’s important to note that certain health conditions, like severe heart or kidney problems, pregnancy, or recent heart attacks, may prevent someone from joining the study. Overall, this trial aims to improve how doctors diagnose heart issues, potentially leading to better treatments for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older;
• • Patients with symptoms of myocardial ischemia such as angina pectoris, who have CAG showing \<70% stenosis at the most severe site or CTA showing non-severe stenosis
• • Signed informed consent.
• Exclusion Criteria:
• • Patients with absolute or relative contraindications to SPECT-loaded myocardial perfusion, including acute myocardial infarction within 48 hours, significant left main coronary artery stenosis, bronchial asthma, and adenosine injection allergy;
• • Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy, or moderate or severe valvular disease;
• • Patients with Hemodynamic instability (systolic blood pressure\<90 mmHg, or who requires vasoactive drugs), or patients with tachyarrhythmia, Ⅱdegree atrioventricular block and above that have not returned to normal;
• • Patients who have severe renal abnormality with eGFR \<30 ml/min, or patients who are on dialysis;
• • Patients with malignant tumors with predicted survival of less than 1 year;
• • Pregnant or breastfeeding women;
• • Patients who are unable to enter the MCG device, who are unable to perform MCG examination due to interference from metal implants or other reasons, or who are deemed by the investigators to be unsuitable for enrollment.